Product structure：二、Reaction characteristics：PSMA1007是一种特异性膜抗原PSMA抑制剂，通过与PSMA结合，能够抑制其介导的生物学功能。PSMA是一种FBP酶，具有良好的亲和力和特异性。其通过与PSMA的胞内域结合，抑制其介导的生物学功能。PSMA1007是由两种主要单体构成的聚合物，一种是苯乙烯，另一种是丙烯酸。通过控制...
Chemical Structure PSMA-1007 CAS# 2093321-19-6 Instruction Theoretical Analysis MedKoo Cat#: 463146 Name: PSMA-1007 CAS#: 2093321-19-6 Chemical Formula: C49H55FN8O16 Exact Mass: 1,030.37 Molecular Weight: 1,031.017 Elemental Analysis: C, 57.08; H, 5.38; F, 1.84; N, 10.87...
PSMA-1007 产品编号T69924Cas号2093321-19-6 PSMA-1007 is a novel Glu-Ureido-type prostate-specific membrane antigen (PSMA) inhibitor. 规格价格库存数量 25 mg¥ 17,20010-14周 50 mg¥ 22,80010-14周 100 mg¥ 29,50010-14周 大包装 & 定制...
英文名：DCL (PSMA inhibitor) (ACUPA)中文名：DCL (PSMA inhibitor) (ACUPA)分子量：319.31 g/mol 纯度：0.98 分子式：C12H21N3O7 Chemical Structure Description A chemical structure of a molecule includes the arrangement of atoms and the chemical bonds that hold the atoms together. The DCL (...
其中一种常用的配体是PSMA-1007，它是一种合成的PSMA配体，具有高亲和力和特异性P。PSMA-ligand-1在前列腺癌中具有重要的表达，放射性配体疗法针对PSMA作为治疗靶点。Product structure：Product specifications：1.CAS No：1610413-97-2 2.Molecular formula：C34H54N4O10 3.Molecular weight：678.813 4.Packaging ...
Ligand optimization showed that the new backbone structure leads to high-affinity PSMA ligands (all IC50 < 50 nM). Moreover, ligand-mediated PDT led to a PSMA-specific decrease in cell viability in vitro (P < 0.001). Linker modification significantly improved tumor targeting compared to the ...
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. Article CAS Google Scholar Capobianco N, Sibille L, Chantadisai M, Gafita A, Langbein T, Platsch G, ...
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1929–1930. [CrossRef] [PubMed] 21. Giesel, F.L.; Hadaschik, B.; Cardinale, J.; Radtke, J.; Vinsensia, M.; ...
The radiosynthesis of [18F]F-PSMA-1007, which resembles the structure of the therapeutic agent PSMA-617 [21], was performed using a simplified one-step automated method, which was followed by the direct radio-fluorination of the precursor (5-((S)-4-carboxy-1-((S)-4-carboxy-1-(4-((...
[18F]PSMA-1007. Ten additional mice bearing C4-2 xenografts were subjected to ex vivo biodistribution with either [18F]AlF-PSMA-11 (n = 5) or [18F]PSMA-1007 (n = 5). Absolute SUVmeanand SUVmaxvalues were significantly higher for [18F]PSMA-1007 scans in both C4-2 tumors (...